Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies ...
Business Wire1mon
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
Ribrecabtagene autoleucel is an autologous anti-BCMA CAR-T therapy that utilizes a humanized single-domain antibody as the antigen ... acetyl transferases CBP and p300. Aurigene also has a strong ...